Results 31 to 40 of about 862,104 (211)

Blockade of catecholamine-induced growth by adrenergic and dopaminergic receptor antagonists in Escherichia coli O157:H7, Salmonella enterica and Yersinia enterocolitica

BMC Microbiology, 2007
Background The ability of catecholamines to stimulate bacterial growth was first demonstrated just over a decade ago. Little is still known however, concerning the nature of the putative bacterial adrenergic and/or dopaminergic receptor(s) to which ...
Lyte Mark, Haigh Richard D, Freestone Primrose PE   +2 more
doaj   +1 more source

Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database

Scientific Reports
Voriconazole is a second-generation azole used to treat serious fungal infections. Visual hallucinations constitute a representative adverse event caused by voriconazole. However, its mechanism of action remains unclear. In patients with schizophrenia or
Hideo Kato, Chihiro Shiraishi, Mao Hagihara, Hiroshige Mikamo, Takuya Iwamoto   +4 more
doaj   +1 more source

The anti-influenza drug oseltamivir evokes hypothermia in mice through dopamine D2 receptor activation via central actions

Journal of Pharmacological Sciences, 2018
Oseltamivir has a hypothermic effect in mice when injected intraperitoneally (i.p.) and intracerebroventricularly (i.c.v.). Here we show that the hypothermia evoked by i.c.v.-oseltamivir is inhibited by non-selective dopamine receptor antagonists ...
Akihiro Fukushima, Arisa Fukui, Yuki Takemura, Yasuhiro Maeda, Hideki Ono   +4 more
doaj   +1 more source

PDE10A Inhibitors—Clinical Failure or Window Into Antipsychotic Drug Action?

Frontiers in Neuroscience, 2021
PDE10A, a phosphodiesterase that inactivates both cAMP and cGMP, is a unique signaling molecule in being highly and nearly exclusively expressed in striatal medium spiny neurons.
Frank S. Menniti, Thomas A. Chappie, Christopher J. Schmidt   +2 more
doaj   +1 more source

Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice

Neurobiology of Disease, 2010
Adenosine A2A receptor (A2AR) antagonists are being investigated as promising treatment strategy for Parkinson's disease (PD). To test whether A2AR antagonists are beneficial in early PD stages we used MitoPark mice, a genetic model with gradual ...
Daniel Marcellino, Eva Lindqvist, Marion Schneider, Christa E. Müller, Kjell Fuxe, Lars Olson, Dagmar Galter   +6 more
doaj   +1 more source

Effect of intermittent subchronic MK‐801 administration on dopamine synthesis capacity and responsiveness in the prefrontal cortex

Neuropsychopharmacology Reports
Aim The therapeutic potential of N‐methyl‐D‐aspartate glutamate receptor (NMDAR) antagonists, particularly ketamine, in mood disorders, is linked to their modulation of dopamine dynamics in the medial prefrontal cortex (mPFC).
Kazuro Shibata, Kosuke Enomoto, Takahiro Tsutsumi, Hiroyuki Muraoka, Tatsu Fuwa, Masahiko Kawano, Jun Ishigooka, Ken Inada, Katsuji Nishimura, Hidehiro Oshibuchi   +9 more
doaj   +1 more source

Adenosine A𝟐A Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's Disease

Parkinson's Disease, 2012
Parkinson's disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra. Current treatments for PD focus on dopaminergic therapies, including L-dopa and dopamine receptor agonists.
Carina J. Bleickardt, Abigail L. LaShomb, Carrie E. Merkel, Robert A. Hodgson   +3 more
doaj   +1 more source

Management of Acute Migraine in Children

Pediatric Neurology Briefs, 2007
The management of acute pediatric migraine headaches in the pediatric emergency department (ED) and in a mixed pediatric and adult ED was compared at the University of Alberta, Edmonton, Canada.
J Gordon Millichap
doaj   +1 more source

A2A Receptor Antagonism and Dyskinesia in Parkinson’s Disease

Parkinson's Disease, 2012
Dyskinesia, a major complication of treatment of Parkinson’s disease (PD), involves two phases: induction, which is responsible for dyskinesia onset, and expression, which underlies its clinical manifestation.
Micaela Morelli, Fabio Blandini, Nicola Simola, Robert A. Hauser   +3 more
doaj   +1 more source

Could Dopamine Agonists Aid in Drug Development for Anorexia Nervosa?

Frontiers in Nutrition, 2014
Anorexia nervosa is a severe psychiatric disorder most commonly starting during the teenage years and associated with food refusal and low body weight. Typically there is a loss of menses, intense fear of gaining weight and an often delusional quality of
Guido eFrank
doaj   +1 more source